Last reviewed 2026-05-14 · How we verify

EryDex High dose DSP

Quince Therapeutics S.p.A. · Phase 3 active Small molecule

EryDex High dose DSP is a Corticosteroid Small molecule drug developed by Quince Therapeutics S.p.A.. It is currently in Phase 3 development for Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3). Also known as: EryDex System end product.

EryDex High dose DSP is a dexamethasone formulation designed for enhanced delivery and bioavailability in treating inflammatory and immune-mediated conditions.

EryDex High dose DSP is a dexamethasone formulation designed for enhanced delivery and bioavailability in treating inflammatory and immune-mediated conditions. Used for Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3).

Likelihood of approval

59.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EryDex High dose DSP
Also known as	EryDex System end product
Sponsor	Quince Therapeutics S.p.A.
Drug class	Corticosteroid
Target	Glucocorticoid receptor
Modality	Small molecule
Therapeutic area	Immunology / Inflammatory disease
Phase	Phase 3

Mechanism of action

DSP (Dexamethasone Sodium Phosphate) is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors. The 'High dose' designation and proprietary formulation suggest optimization for systemic delivery and efficacy in severe inflammatory or autoimmune disorders. Quince Therapeutics' approach likely focuses on improved pharmacokinetics or reduced adverse effects compared to standard dexamethasone formulations.

Approved indications

Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3)

Common side effects

Hyperglycemia
Immunosuppression / increased infection risk
Hypertension
Insomnia / mood changes
Osteoporosis (with chronic use)

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EryDex High dose DSP CI brief — competitive landscape report
EryDex High dose DSP updates RSS · CI watch RSS
Quince Therapeutics S.p.A. portfolio CI

Frequently asked questions about EryDex High dose DSP

What is EryDex High dose DSP?

EryDex High dose DSP is a Corticosteroid drug developed by Quince Therapeutics S.p.A., indicated for Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3).

How does EryDex High dose DSP work?

EryDex High dose DSP is a dexamethasone formulation designed for enhanced delivery and bioavailability in treating inflammatory and immune-mediated conditions.

What is EryDex High dose DSP used for?

EryDex High dose DSP is indicated for Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3).

Who makes EryDex High dose DSP?

EryDex High dose DSP is developed by Quince Therapeutics S.p.A. (see full Quince Therapeutics S.p.A. pipeline at /company/quince-therapeutics-s-p-a).

Is EryDex High dose DSP also known as anything else?

EryDex High dose DSP is also known as EryDex System end product.

What drug class is EryDex High dose DSP in?

EryDex High dose DSP belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is EryDex High dose DSP in?

EryDex High dose DSP is in Phase 3.

What are the side effects of EryDex High dose DSP?

Common side effects of EryDex High dose DSP include Hyperglycemia, Immunosuppression / increased infection risk, Hypertension, Insomnia / mood changes, Osteoporosis (with chronic use).

What does EryDex High dose DSP target?

EryDex High dose DSP targets Glucocorticoid receptor and is a Corticosteroid.

Drug class: All Corticosteroid drugs
Target: All drugs targeting Glucocorticoid receptor
Manufacturer: Quince Therapeutics S.p.A. — full pipeline
Therapeutic area: All drugs in Immunology / Inflammatory disease
Indication: Drugs for Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3)
Also known as: EryDex System end product

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing